Amgen Gets FDA Approval to Reduce Monitoring Time for First Two Imdelltra Doses

09:51 AM EDT, 09/14/2026 (MT Newswires) -- Amgen (AMGN) said Monday that the US Food and Drug Administration approved reduced monitoring time for the first two doses of Imdelltra in patients with extensive-stage small cell lung cancer. Patients should now be monitored for 6 to 8 hours from the start of their first two infusions, down from the previously recommended 22 to 24 hours, the company said. Patients will also receive a follow-up assessment, including vital signs, the day after each of the first two doses, Amgen said. Price: 379.09, Change: +1.74, Percent Change: +0.46